Lipomedics Inc. and Autotelic Inc. Announce Presentation on Nanoparticle Paclitaxel

FORT WORTH, Texas - Nov. 16, 2015 - PRLog -- Paclitaxel is one of the most effective chemotherapeutic drugs currently available and is used to treat mainly breast, lung and ovarian cancers. It has been formulated as a nanoparticle formulation, Abraxane, to improve its solubility and to avoid the use of harmful solvents like cremophor EL. We previously reported the next generation Abraxane – Cynviloq – a polymeric micelle paclitaxel formulation which uses a chemical polymer instead of a biological polymer to stabilize the nanoparticle. Cynviloq is currently being developed by NantPharma. Here we report the use of phospholipids instead of a chemical polymer for the creation of the next generation Abraxane.

The effect of lipid composition and methods of preparation on drug loading and physical stability of the paclitaxel-loaded lipid-coated nanoparticle formulation were evaluated. The optimization of phospholipid composition, phospholipid types and process parameters led to a physically stable paclitaxel-loaded phospholipid-coated nanoparticulate formulation that maintains size, charge and integrity during storage.

The poster presentation will be held at SFNano Nanomed Europe Grenoble 2015 meeting in the Minatec Building during the lunch breaks on:

December 8, 2015, 12:20 - 2pm

December 9, 2015, 12:00 - 1:45pm
"Injectable Phospholipid-Coated Nanoparticles Loaded with Paclitaxel: Influence of Lipid Composition, Methods of Preparation, Drug Concentration and Storage Temperatures"
Authors: Shradha Prabhulkar, Gary Williams, Steve Miller, Zachary Yim, Walter McConathy, Tapas De

LipoMedics Inc., 3400 Camp Bowie Blvd, Fort Worth, Texas 76107,USA

Contact:tde@autotelicinc.com

About Paclitaxel

Paclitaxel is a hydrophobic mitotic inhibitor with a powerful anticancer effect. It belongs to the group of taxanes (together with docetaxel), which are potent cytotoxic diterpenes derived from yew trees. Paclitaxel is active against a spectrum of malignancies that are generally considered to be refractory to conventional therapy.

About SFNano

SFNano is a non profit-making organization whose aim is to promote the advancement and dissemination of knowledge in the field of nano-medicine. SFNano stimulates the exchanges among the main players from academia and industry in France while reaching out across borders to their European neighbors. Nanomedicine includes nanotechnologies devoted to diagnosis, therapy, imaging and regenerative medicine.

About Autotelic Inc.

Autotelic works through our partners to transform how medications are being delivered. The Autotelic Inc. platform is our Therapeutic Drug Monitoring (TDM) device which allows PK guided dosing, reducing the toxicity from overmedication and increasing the efficacy from under-medication. Current dosing schemes result in either too much drug exposure or too little drug exposure because of individual pharmacokinetic variations. Our pipeline includes TDM devices for management of oncology, hypertension and pain.

About LipoMedics Inc.

LipoMedics Inc. is developing personalized paclitaxel therapy based on our proprietary Therapeutic Drug Monitoring (TDM) device and our platform for delivery of water insoluble drugs including paclitaxel. The company's platform technology is the phospholipid paclitaxel nanoparticle that upon injection disperses paclitaxel in the plasma compartment. This paclitaxel/phospholipids formulation represents the “Next Generation of Paclitaxel Nanomedicine”.

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. We caution you that any forward-looking information provided by or on our behalf is not a guarantee of future performance. Forward-looking statements include: (I) changes in domestic and foreign economic or non-economic conditions, (II) the effect of federal, state and foreign FDA regulations, (III) Intellectual property and other claims, (IV) the effect of our clinical and non-clinical trial, (V) the impact on our branding strategy and other factors. All such forward-looking statements are current only as of the date on which such statements are made. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.